Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges

Over the past decade, there have been several guideline updates for the diagnosis and management of non-alcoholic fatty liver disease (NAFLD), which is the most common chronic liver disease affecting approximately one-third of the world's population [1–3]. These changes were necessitated by our evolving understanding of the disease, the name of which has also recently been changed from “NAFLD”, resulting from a lack of mechanistic understanding, to metabolic dysfunction-associated steatotic liver disease (MASLD), and from non-alcoholic steatohepatitis (NASH) to metabolic dysfunction-associated steatohepatitis (MASH) [4–6].